NDC 67184-0530

Bortezomib

Bortezomib

Bortezomib is a Intravenous; Subcutaneous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Qilu Pharmaceutical Co., Ltd.. The primary component is Bortezomib.

Product ID67184-0530_7f2d7d7b-99b3-4b68-9bbd-89a8249c66a0
NDC67184-0530
Product TypeHuman Prescription Drug
Proprietary NameBortezomib
Generic NameBortezomib
Dosage FormInjection, Powder, Lyophilized, For Solution
Route of AdministrationINTRAVENOUS; SUBCUTANEOUS
Marketing Start Date2022-05-02
Marketing CategoryANDA /
Application NumberANDA210824
Labeler NameQilu Pharmaceutical Co., Ltd.
Substance NameBORTEZOMIB
Active Ingredient Strength4 mg/1
Pharm ClassesProteasome Inhibitor [EPC], Proteasome Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Drug Details

NDC Crossover Matching brand name "Bortezomib" or generic name "Bortezomib"

NDCBrand NameGeneric Name
0143-9098bortezomibbortezomib
0409-1700BortezomibBortezomib
0409-1703BORTEZOMIBBORTEZOMIB
0409-1704BORTEZOMIBBORTEZOMIB
0781-3258bortezomibbortezomib for injection
10019-991BORTEZOMIBbortezomib
25021-244BORTEZOMIBBORTEZOMIB
43598-426BortezomibBortexomib
43598-865BortezomibBortexomib
50742-484BortezomibBortezomib
51817-586Bortezomibbortezomib
55150-337BORTEZOMIBBORTEZOMIB
60505-6050BORTEZOMIBbortezomib
63323-721BortezomibBortezomib
63323-821BortezomibBortezomib
67184-0530BortezomibBortezomib
68001-534BortezomibBortezomib
68001-540BortezomibBortezomib
68001-541BortezomibBortezomib
70511-161Bortezomibbortezomib
70511-162Bortezomibbortezomib
70710-1411BORTEZOMIBBORTEZOMIB
70771-1708BORTEZOMIBBORTEZOMIB
70860-225Bortezomibbortezomib
71288-118BortezomibBortezomib
72205-183BortezomibBortezomib
72266-243Bortezomibbortezomib
72266-244Bortezomibbortezomib
63020-049VELCADEbortezomib
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.